{"schema_version":"secwatch.filing_event.v1","accession":"0001398733-25-000022","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2025-10-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.306182+00:00","generated_at":"2026-05-17T04:18:14.899426+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aquestive receives two new US patents for Anaphylm, extending protection to 2037","bullets":["USPTO issued U.S. patent nos. 12,427,121 and 12,443,850 covering epinephrine prodrug compositions for sublingual film delivery.","Patents expire May 4, 2037, subject to extensions; protect proprietary composition enabling oral film delivery.","Anaphylm (dibutepinephrine) sublingual film, if FDA approved, would be first oral rescue treatment for severe allergic reactions.","PDUFA target action date for Anaphylm is January 31, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001398733-25-000022","json":"https://secwatch.observer/filing/0001398733-25-000022.json","markdown":"https://secwatch.observer/filing/0001398733-25-000022.md","text":"https://secwatch.observer/filing/0001398733-25-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000139873325000022/0001398733-25-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000139873325000022/aqst-20251008.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:18:14.899426+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}